SCAMP5

SCAMP5 is a brain-enriched vesicle membrane protein that orchestrates multiple steps of synaptic vesicle cycling, secretory trafficking, and presynaptic homeostasis. It promotes synaptic vesicle endocytosis during high neuronal activity and facilitates active-zone release site clearance through direct interaction of its 2/3 loop domain with AP-2, while also recruiting the cation/H⁺ exchanger NHE6 to glutamatergic presynaptic terminals to regulate vesicle luminal pH and glutamate quantal size (PMID:25057210, PMID:29562188, PMID:33372133). SCAMP5 binds PI4KB at the trans-Golgi network to drive PtdIns4P-dependent AP-4-mediated ATG9A trafficking, thereby controlling presynaptic autophagosome biogenesis, and interacts with synaptotagmin-1 and SNARE machinery to regulate calcium-triggered exocytosis—functions disrupted by the autism/epilepsy-associated R91W mutation (PMID:40958389, PMID:19234194, PMID:32020363). In pancreatic β-cells, SCAMP5 interacts with VDAC1 to suppress Bax-dependent apoptosis and supports insulin secretion, with its expression epigenetically repressed by hyperglycemia-activated ChREBP (PMID:40953307).

1. 2009 High

   Establishing SCAMP5 as a participant in calcium-regulated exocytosis resolved its role beyond generic vesicle trafficking, showing it bridges Golgi-derived compartments to the plasma membrane through interactions with synaptotagmins and SNARE complexes.

   Evidence Subcellular fractionation, Co-IP, confocal imaging, and cytokine secretion assays in human epithelial cells, monocytes, and macrophages

   PMID:19234194

   Open questions at the time

   • Whether SCAMP5-synaptotagmin interaction is direct or scaffold-mediated was not fully resolved
   • The specific SNARE partners in the complex were not individually identified
   • Relevance to neuronal synaptic vesicle exocytosis was not tested
2. 2009 Medium

   Demonstrating that ER stress-induced SCAMP5 upregulation impairs endocytosis and promotes mutant huntingtin aggregation revealed SCAMP5 as a modulator of endocytic flux with disease relevance.

   Evidence SCAMP5 overexpression and knockdown in striatal neurons; in vivo tunicamycin injection in Huntington's disease mouse models

   PMID:19240033

   Open questions at the time

   • Mechanism by which SCAMP5 impairs endocytosis was not defined
   • Whether the endocytic impairment is direct or secondary to ER stress signaling remains unclear
3. 2010 Medium

   Identifying SCAMP5 as a negative regulator of large dense-core vesicle secretion in β-cells extended its function beyond constitutive trafficking to regulated secretion in endocrine cells.

   Evidence shRNA knockdown and overexpression in beta-TC3 cells with stimulated secretion assays

   PMID:20071347

   Open questions at the time

   • The molecular mechanism of secretion suppression was not identified
   • Whether the effect is specific to LDCVs or extends to other vesicle types in β-cells was untested
4. 2014 High

   Demonstrating that SCAMP5 is selectively required for synaptic vesicle endocytosis during intense neuronal activity established its activity-dependent role at the presynaptic terminal.

   Evidence shRNA knockdown with rescue in cultured rat hippocampal neurons; optical imaging of SV recycling pools

   PMID:25057210

   Open questions at the time

   • The endocytic adaptor or coat machinery engaged by SCAMP5 was not identified
   • Whether SCAMP5 acts in clathrin-mediated versus bulk endocytosis was unclear
5. 2018 High

   Mapping the 2/3 loop domain of SCAMP5 as the site of direct AP-2 interaction and showing its requirement for active-zone release site clearance resolved the molecular basis for its endocytic function and explained the synaptic depression phenotype.

   Evidence Domain truncation mapping, super-resolution microscopy, electrophysiology, knockdown in hippocampal neurons

   PMID:29562188

   Open questions at the time

   • Whether SCAMP5-AP2 interaction recruits clathrin or other coat proteins was not determined
   • Structural basis of the 2/3 loop–AP2 interaction is unknown
6. 2020 Medium

   The R91W knock-in mouse showed that a disease-associated SCAMP5 mutation disrupts synaptotagmin-1 interaction and shifts excitation/inhibition balance, providing a mechanistic link from molecular interaction to circuit-level dysfunction relevant to autism and epilepsy.

   Evidence Knock-in mouse model, single-neuron electrophysiology, protein interaction analysis

   PMID:32020363

   Open questions at the time

   • Whether the R91W mutation also affects the AP-2 or NHE6 interactions was not tested
   • Behavioral phenotyping of R91W mice was limited
7. 2021 High

   Identifying the SCAMP5–NHE6 interaction via the 2/3 loop domain and demonstrating genetic epistasis with NHE6 KO established SCAMP5 as the trafficking receptor that recruits NHE6 to presynaptic terminals, controlling vesicle pH and glutamate quantal size.

   Evidence Domain mapping, shRNA knockdown, NHE6 KO epistasis, electrophysiology and optical imaging in hippocampal neurons

   PMID:33372133 PMID:33663553

   Open questions at the time

   • Whether SCAMP5 simultaneously binds AP-2 and NHE6 or these are mutually exclusive interactions is unknown
   • Whether NHE6 recruitment by SCAMP5 occurs at the Golgi, endosome, or plasma membrane was not resolved
8. 2025 High

   Discovery that SCAMP5 binds PI4KB to control TGN PtdIns4P levels, AP-4 recruitment, and ATG9A trafficking to presynaptic sites established SCAMP5 as a key organizer of presynaptic autophagy, a previously unrecognized function.

   Evidence Co-IP for SCAMP5-PI4KB interaction, knockdown with fluorescence imaging of ATG9A trafficking and autophagosome formation in hippocampal neurons

   PMID:40958389

   Open questions at the time

   • Whether the PI4KB interaction uses the same 2/3 loop domain as AP-2 and NHE6 interactions is unknown
   • Whether presynaptic autophagy deficits contribute to neurodegeneration in SCAMP5 mutant models was not tested
9. 2025 Medium

   Identifying the SCAMP5–VDAC1 interaction in β-cells and showing that SCAMP5 loss triggers Bax-mediated apoptosis revealed a non-neuronal cytoprotective function, while ChREBP-mediated epigenetic silencing under hyperglycemia provided a disease-relevant regulatory mechanism.

   Evidence Co-IP, knockdown/overexpression in β-cell lines, ChIP for H3K4me3 at Scamp5 promoter, apoptosis and secretion assays

   PMID:40953307

   Open questions at the time

   • Whether SCAMP5 directly downregulates VDAC1 protein or acts through an intermediate is unclear
   • In vivo β-cell-specific SCAMP5 knockout has not been reported
10. 2025 Medium

    Linking SCAMP5 deficiency to α-synuclein accumulation, impaired exosomal secretion, and dopamine neuron loss in zebrafish connected SCAMP5 dysfunction to Parkinson's disease-like pathology.

    Evidence Knockdown in PC12 and SH-SY5Y cells, exosome isolation, scamp5a knockout zebrafish with transcriptome analysis

    PMID:41186735

    Open questions at the time

    • Whether α-synuclein accumulation is due to impaired secretion, impaired autophagy, or both was not disambiguated
    • Mammalian in vivo validation of the Parkinson's-like phenotype is lacking

• It remains unknown how SCAMP5 coordinates its multiple binding partners (AP-2, NHE6, PI4KB, synaptotagmin-1, VDAC1) — whether interactions are mutually exclusive, compartment-specific, or regulated by post-translational modifications — and no structural model of any SCAMP5 complex exists.
• No high-resolution structure of SCAMP5 or any SCAMP5-partner complex
• Post-translational modifications that might switch between interaction partners are uncharacterized
• Conditional knockout mouse models for SCAMP5 in brain have not been reported